DENTSPLY SIRONA (NASDAQ:XRAY) Issues Q2 2025 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.500-0.520 for the period, compared to the consensus estimate of 0.497. The company issued revenue guidance of $935.0 million-$935.0 million, compared to the consensus revenue estimate of $931.3 million.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on XRAY shares. Barrington Research boosted their price objective on shares of DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. Wall Street Zen upgraded shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a report on Sunday, July 13th. UBS Group reduced their price objective on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Needham & Company LLC restated a "hold" rating on shares of DENTSPLY SIRONA in a report on Monday. Finally, Piper Sandler decreased their target price on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Ten research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $19.60.

DENTSPLY SIRONA Stock Performance

XRAY stock traded down $0.05 during trading hours on Monday, hitting $15.63. 5,103,404 shares of the stock were exchanged, compared to its average volume of 2,914,792. The company has a 50-day simple moving average of $16.07 and a two-hundred day simple moving average of $16.26. The firm has a market capitalization of $3.11 billion, a P/E ratio of 9.33, a P/E/G ratio of 1.12 and a beta of 0.94. The company has a current ratio of 1.10, a quick ratio of 0.76 and a debt-to-equity ratio of 0.79. DENTSPLY SIRONA has a 12 month low of $12.16 and a 12 month high of $27.95.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.14. The business had revenue of $879.00 million during the quarter, compared to analyst estimates of $854.75 million. DENTSPLY SIRONA had a positive return on equity of 14.31% and a negative net margin of 24.42%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 EPS. On average, analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 11th. Investors of record on Friday, June 27th were paid a dividend of $0.16 per share. The ex-dividend date was Friday, June 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.09%. DENTSPLY SIRONA's payout ratio is currently -14.10%.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier's stock worth $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier's stock valued at $376,000 after purchasing an additional 9,355 shares during the last quarter. Empowered Funds LLC boosted its stake in DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock worth $244,000 after acquiring an additional 1,320 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the first quarter valued at approximately $26,000. Institutional investors and hedge funds own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.